Linagliptin/Metformin Clonmel

Linagliptin, the active ingredient in Linagliptin/Metformin Clonmel, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is combined with metformin hydrochloride, a biguanide, to treat type 2 diabetes mellitus in adult patients when diet, exercise, and monotherapy are insufficient.

GNH USA supplies Linagliptin/Metformin Clonmel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU quality standards and is manufactured under GMP conditions.

Linagliptin/Metformin is indicated for the management of type 2 diabetes mellitus, acting on glucose regulation pathways. - Type 2 diabetes mellitus: improves overall glycemic control when monotherapy is inadequate. - Adults with type 2 diabetes inadequately controlled on metformin alone: provides additional glucose‑lowering effect. - Patients requiring combination therapy: offers dual mechanisms to reduce fasting and post‑prandial glucose levels.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhoea: loose stools, often transient. - Abdominal discomfort: cramping or pain. - Headache: mild tension‑type headaches. - Dizziness: occasional light‑headedness. - Hypoglycaemia (when combined with sulfonylureas or insulin): low blood sugar episodes.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Renal impairment: worsening kidney function. - Severe hypoglycaemia: prolonged low blood glucose requiring assistance.

Before initiating therapy, clinicians should evaluate patient‑specific factors. - Renal function assessment: check eGFR to ensure safe metformin use. - Hepatic disease monitoring: assess liver enzymes periodically. - Risk of lactic acidosis: avoid in patients with severe renal or hepatic impairment. - Pregnancy and lactation: prescribe only if benefits outweigh potential risks. - Drug interaction review: consider concomitant medications that may affect glucose control. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Linagliptin/Metformin may interact with several medicines; monitoring is essential. Major Interactions (Avoid): - Severe renal impairment (eGFR <30 mL/min/1.73 m²): contraindicates metformin use. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure. - Iodinated contrast agents: can precipitate metformin‑associated lactic acidosis. Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: heightened risk of hypoglycaemia, dose adjustments may be needed. - Alcohol consumption: may increase the risk of metformin‑related lactic acidosis.